

Martin J Bergman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6677589/publications.pdf>

Version: 2024-02-01

32
papers

1,895
citations

840585

11
h-index

526166

27
g-index

33
all docs

33
docs citations

33
times ranked

2744
citing authors

#	ARTICLE	IF	CITATIONS
1	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 3-15.	0.5	1,114
2	The Prevalence and Characteristics of Fibromyalgia in the 2012 National Health Interview Survey. <i>PLoS ONE</i> , 2015, 10, e0138024.	1.1	202
3	2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures. <i>Arthritis Care and Research</i> , 2019, 71, 1540-1555.	1.5	157
4	Is Fatigue an Inflammatory Variable in Rheumatoid Arthritis (RA)? Analyses of Fatigue in RA, Osteoarthritis, and Fibromyalgia. <i>Journal of Rheumatology</i> , 2009, 36, 2788-2794.	1.0	76
5	Three-Quarters of Persons in the US Population Reporting a Clinical Diagnosis of Fibromyalgia Do Not Satisfy Fibromyalgia Criteria: The 2012 National Health Interview Survey. <i>PLoS ONE</i> , 2016, 11, e0157235.	1.1	66
6	Patient Expectations and Perceptions of Goal-setting Strategies for Disease Management in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2015, 42, 2046-2054.	1.0	58
7	Evaluation of Adherence and Persistence Differences Between Adalimumab Citrate-Free and Citrate Formulations for Patients with Immune-Mediated Diseases in the United States. <i>Rheumatology and Therapy</i> , 2021, 8, 109-118.	1.1	25
8	Adaptation of American College of Rheumatology Rheumatoid Arthritis Disease Activity and Functional Status Measures for Telehealth Visits. <i>Arthritis Care and Research</i> , 2021, 73, 1809-1814.	1.5	22
9	Clinical Utility and Cost Savings in Predicting Inadequate Response to Anti-TNF Therapies in Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2020, 7, 775-792.	1.1	19
10	Upadacitinib improves patient-reported outcomes <i>vs</i> placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE. <i>Rheumatology</i> , 2021, 60, 5583-5594.	0.9	17
11	High Burden of Burnout on Rheumatology Practitioners. <i>Journal of Rheumatology</i> , 2020, 47, 1831-1834.	1.0	15
12	Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY. <i>Rheumatology</i> , 2021, 60, 3209-3221.	0.9	14
13	Methods for Developing the American College of Rheumatology's Electronic Clinical Quality Measures. <i>Arthritis Care and Research</i> , 2016, 68, 1402-1409.	1.5	13
14	Data-Driven Patient Clustering and Differential Clinical Outcomes in the Brigham and Women's Rheumatoid Arthritis Sequential Study Registry. <i>Arthritis Care and Research</i> , 2021, 73, 471-480.	1.5	12
15	Routine Assessment of Patient Index Data 3 and the American College of Rheumatology/European League Against Rheumatism Provisional Remission Definitions as Predictors of Radiographic Outcome in a Rheumatoid Arthritis Clinical Trial With Tocilizumab. <i>Arthritis Care and Research</i> , 2017, 69, 609-615.	1.5	11
16	Managing morbidity and treatment-related toxicity in patients with ankylosing spondylitis. <i>Rheumatology</i> , 2018, 57, 419-428.	0.9	11
17	Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada. <i>Rheumatology International</i> , 2017, 37, 1111-1123.	1.5	10
18	Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials. <i>Rheumatology</i> , 2020, 59, 2090-2098.	0.9	10

#	ARTICLE	IF	CITATIONS
19	Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials. <i>Clinical Rheumatology</i> , 2018, 37, 2043-2053.	1.0	9
20	Healthcare Costs of Not Achieving Remission in Patients with Rheumatoid Arthritis in the United States: A Retrospective Cohort Study. <i>Advances in Therapy</i> , 2021, 38, 2558-2570.	1.3	6
21	Cost per response for abatacept versus adalimumab in patients with seropositive, erosive early rheumatoid arthritis in the US, Germany, Spain, and Canada. <i>Rheumatology International</i> , 2019, 39, 1621-1630.	1.5	5
22	Healthcare Resource Use in Patients with Immune-Mediated Conditions Treated with Targeted Immunomodulators During COVID-19 Pandemic: A Retrospective Claims Analysis. <i>Advances in Therapy</i> , 2021, 38, 5302-5316.	1.3	5
23	Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis. <i>Advances in Therapy</i> , 2021, 38, 5649-5661.	1.3	4
24	Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2022, 49, 694-699.	1.0	4
25	Comment on: "It can't be zero!" Difficulties in completing patient global assessment in rheumatoid arthritis: a mixed methods study. <i>Rheumatology</i> , 2021, 60, e28-e29.	0.9	3
26	Low-dose SoluMatrix diclofenac in patients with osteoarthritis pain: impact on quality of life in a controlled trial. <i>Clinical Rheumatology</i> , 2017, 36, 1357-1367.	1.0	2
27	FRIO137...UPADACITINIB IMPROVES PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE: RESULTS FROM SELECT-COMPARE. , 2019, , .		2
28	Guided therapy selection in rheumatoid arthritis using a molecular signature response classifier: an assessment of budget impact and clinical utility. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 1734-1742.	0.5	2
29	Safety of jakinibs: lessons from ORAL Surveillance. <i>Rheumatology</i> , 2022, 61, 4223-4225.	0.9	1
30	THU0448...DISEASE BURDEN IN OSTEOARTHRITIS (OA) IS SIMILAR TO RHEUMATOID ARTHRITIS (RA) FROM THE PATIENT'S PERSPECTIVE, SLIGHTLY HIGHER IN RA AT PRESENTATION, SIMILAR ONE YEAR LATER, AND SLIGHTLY HIGHER IN OA TWO YEARS LATER AT ONE PRIVATE PRACTICE SETTING. , 2019, , .		0
31	Reply. <i>Arthritis Care and Research</i> , 2020, 72, 736-738.	1.5	0
32	Use of Precision Medicine to Guide Treatment of Patients With Rheumatoid Arthritis: Comment on the Article by Tao et al. <i>Arthritis and Rheumatology</i> , 2021, 73, 1567-1569.	2.9	0